Assessing the Value of Medicines-Reference-Cited by-同舟云学术

Assessing the Value of Medicines

Published:2010-04 Issue:2 Volume:24 Page:89-92
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Sansom Lloyd

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF03256802.pdf

Reference12 articles.

1. Fremantle N, Blonde L, Bolinder B, et al. Real-world trials to answer real-world questions. Pharmacoeconomics 2005; 23 (8): 747–54

2. McCabe C, Claxton K, O’Hagan A. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement. Int J Technol Assess Health Care 2008; 24: 140–5

3. Elston J, Taylor R. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom’s health technology reports. Int J Technol Assess Health Care 2009; 25: 6–13

4. Surrogate to Final OutcomesWorking Group report. Report of the Surrogate to Final Outcome Working Group to the Pharmaceutical Benefits Advisory Committee: a framework for evaluating proposed surrogate measures and their use in submissions to PBAC [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/B11E8EF19B358E39CA25754B000A9C07/$File/STFOWG%20paper%20FINAL.pdf [Accessed 2009 Dec 27]

5. Banta D, Oortwijn W. Introduction: health technology assessment and the European Union. Int J Technol Assess Health Care 2000; 16: 299–302

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles;PharmacoEconomics;2016-07-04